Clinical Scorecard: Guidelines for the Management of ATTR-CM in Germany: Consensus from the German Society of Amyloid Diseases and the German Cardiac Society

At a Glance

Key Highlights

• Tafamidis and acoramidis are approved TTR stabilizers; vutrisiran is a TTR gene silencer.

• Tafamidis significantly reduces all-cause mortality and cardiovascular-related hospitalizations.

• Long-term data show sustained survival benefit with early initiation of tafamidis therapy.

• Safety profile of tafamidis is similar to placebo, with mild to moderate adverse events.

• Tafamidis shows efficacy in stabilizing neuropathy in ATTRv patients.

Guideline-Based Recommendations

Diagnosis

• Utilize advanced imaging techniques and clinical evaluations to diagnose ATTR-CM.

Management

• Initiate treatment with tafamidis or acoramidis based on individual patient characteristics.

Monitoring & Follow-up

• Regularly assess cardiac function and monitor for adverse effects during treatment.

Risks

• Consider potential adverse events such as gastrointestinal issues and renal impairment.

Patient & Prescribing Data

Patients diagnosed with ATTR-CM, including those with varying NYHA classes.

Tafamidis has shown efficacy in reducing mortality and improving quality of life metrics.

Clinical Best Practices

• Encourage early initiation of tafamidis therapy for better outcomes.

• Monitor renal function in patients receiving tafamidis, especially those with eGFR ≤ 30 ml/min.

Related Resources & Content

1. German Society of Amyloid Diseases and German Cardiac Society, 2025 -- Guidelines for the Management of ATTR-CM in Germany

2. Clinical Research in Cardiology — Guidelines for the Diagnosis and Management of Cardiac Amyloidosis: A Consensus Statement from the German Cardiac Society (DGK)

3. JAMA Cardiology — Impact of Acoramidis on Health Outcomes in Heart Failure: Insights from a Secondary Analysis of the ATTRibute-CM Study

4. Clinical Research in Cardiology — Evaluating the Diagnostic Utility of Cardiovascular Magnetic Resonance Versus Endomyocardial Biopsy in Cardiac Amyloidosis: A Multi-Center Analysis

5. Clinical Research in Cardiology — Pathophysiological Mechanisms and Treatment Approaches in Cardiac Amyloidosis: Is Inflammation a Contributing Factor?

6. Beyonttra | European Medicines Agency (EMA)

7. Vyndaqel, INN-tafamidis | European Medicines Agency (EMA)

8. Zusammenfassende Dokumentation

9. Nutzenbewertungsverfahren zum Wirkstoff Vutrisiran (Neues Anwendungsgebiet: Wildtyp- oder hereditäre Transthyretin-Amyloidose mit Kardiomyopathie) - Gemeinsamer Bundesausschuss

10. Nuklearkardiologie – Aktueller Stand der klinischen Anwendung | Die Kardiologie | Springer Nature Link

11. https://www.asnc.org/wp-content/uploads/2024/05/19110-ASNC-AND-EANM-Amyloidosis-Practice-Points_LRes19-1.pdf

12. Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy - PubMed

13. Effects of vutrisiran on cardiac structure and function in patients with transthyretin amyloidosis with cardiomyopathy: secondary outcomes of the HELIOS-B trial

14. New Concise Clinical Guidance Addresses Evaluation and Management of ATTR-CM - American College of Cardiology

15. Transthyretin Cardiac Amyloidosis Evaluation and Management: 2025 ACC Concise Clinical Guidance | JACC

16. Relative efficacy of tafamidis, acoramidis, patisiran and vutrisiran in patients with transthyretin cardiac amyloidosis: a network meta-analysis - PMC

17. Relative efficacy of acoramidis, tafamidis and vutrisiran in patients with transthyretin amyloid cardiomyopathy: a multilevel network meta-regression | European Journal of Heart Failure | Oxford Academic

18. Eplontersen trial did not meet its primary endpoint in transthyretin-mediated amyloid cardiomyopathy

19. Eplontersen for Transthyretin Amyloid Cardiomyopathy | New England Journal of Medicine